GET DAILY SIGNALSBeam Therapeutics (BEAM) vs Editas Medicine (EDIT): Weighing Two Gene-Editing Strategies
Key Takeaways
- Different gene-editing technologies: Beam Therapeutics (BEAM) uses base editing, while Editas Medicine (EDIT) uses CRISPR/Cas9 and Cas12 systems.
- Pipeline stage gap: BEAM has multiple clinical-stage programs nearing regulatory filings, while EDIT is pivoting around an early-stage in vivo candidate.
- Balance sheet contrast: BEAM holds roughly $1.2 billion in cash versus about $212 million for EDIT.
- Momentum divergence: EDIT has shown stronger year-to-date gains, but BEAM carries a larger market value and broader pipeline.
- Risk profiles differ: Both remain pre-revenue, clinical-stage biotechs exposed to binary clinical and regulatory outcomes.
- For more context on each company's headlines and daily price action, explore the BEAM Major News, BEAM Today's Price Move, EDIT Major News, and EDIT Today's Price Move pages.
- For automated, data-driven trading ideas across this sector and beyond, explore the curated Trending AI Robots.
Introduction
Beam Therapeutics and Editas Medicine are two clinical-stage biotechnology companies competing at the frontier of genetic medicine, yet they approach the same goal with different tools. Beam has built its platform around base editing, which rewrites single DNA "letters" without cutting the DNA strand, while Editas leverages the better-known CRISPR/Cas9 and Cas12 systems. Both remain pre-revenue and unprofitable, making their share prices highly sensitive to clinical data, regulatory milestones, and cash runway. For growth-oriented and biotech-specialist investors weighing relative performance, market positioning, and pipeline risk, this stock comparison offers a useful framework for understanding how two prominent gene-editing names stack up in the current market environment. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
BEAM Overview and Recent Performance
BEAM is a Cambridge, Massachusetts-based biotechnology company focused on base editing, a precision approach often described as a "molecular pencil" that chemically corrects a single base pair without creating double-stranded DNA breaks. Its lead programs include risto-cel for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency (AATD), and earlier-stage candidates for glycogen storage disease and phenylketonuria.
In recent market activity, the stock has traded in a choppy range. Shares rose sharply after a strong quarterly update earlier in the year but retreated in recent weeks after updated BEAM-302 trial data was described by analysts as solid yet not numerically improved from prior readouts. The company has secured FDA alignment on an accelerated approval pathway for BEAM-302 and has guided toward a biologics license application for risto-cel, creating nearer-term catalysts. With roughly $1.2 billion in cash and a runway projected into mid-2029, BEAM carries one of the stronger balance sheets among gene-editing peers. From what I see, the data updates warrant close monitoring here.
EDIT Overview and Recent Performance
EDIT is a Cambridge, Massachusetts-based genome-editing company built around CRISPR/Cas9 and Cas12 technology. After discontinuing its reni-cel program and restructuring operations, the company has refocused on EDIT-401, an in vivo gene-editing candidate targeting the LDLR gene for heterozygous familial hypercholesterolemia, an inherited cholesterol disorder.
In recent weeks, EDIT has generated notable momentum. The company reported narrowing losses and higher collaboration revenue, presented encouraging preclinical data showing durable LDL reductions in non-human primates, and received clearance to initiate a Phase 1/2 clinical trial in Australia. Shares have climbed substantially year-to-date, though the stock remains in the low single digits with a market capitalization well below its larger peer. With about $212 million in cash expected to fund operations into the second half of 2028, funding and execution risk remain central considerations for investors. I’m watching this closely as the early data comes in.
Head-to-Head Comparison
Although both companies operate in gene editing, their business models and risk profiles diverge in several ways. BEAM has a broader, more advanced pipeline with multiple clinical programs and clearer near-term regulatory paths, supported by a substantially larger cash balance. EDIT is leaner and more concentrated, effectively betting on a single early-stage candidate in a large cardiovascular market.
On growth drivers, BEAM is positioned around near-term data readouts and potential filings, while EDIT is driven by preclinical-to-clinical translation and early human data. In terms of recent momentum, EDIT has delivered stronger percentage gains over the past year, though from a much lower base, while BEAM has been steadier but recently pressured by a mixed data update. Both carry elevated beta and short interest, reflecting high investor debate. Sector exposure is similar, but EDIT's smaller capital base makes it more sensitive to dilution and financing conditions.
Tickeron AI Verdict
Based on observable factors such as trend consistency, balance-sheet stability, and catalyst density, Tickeron's AI would likely express a relative preference for BEAM at present. The company's deeper cash runway, multiple advanced clinical programs, and nearer-term regulatory milestones provide a more diversified and stable setup than a single, early-stage lead asset. That said, EDIT offers a higher-risk, potentially higher-reward profile given its stronger recent momentum and concentrated upside tied to EDIT-401. Any verdict should be viewed as probabilistic rather than definitive, as both names remain exposed to binary clinical outcomes and shifting biotech sentiment.
Exploring AI Tools for Biotech Research
In my own research process, I often turn to Tickeron’s AI Trading Bots to generate systematic ideas across volatile sectors like biotech. The platform offers hundreds of automated strategies that adapt to live market conditions, with a curated Trending AI Robots section highlighting those best suited for current environments. These span different styles, timeframes, and performance metrics, providing a practical way to explore data-driven approaches without replacing personal analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EDIT in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 14, 2026
EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 43 cases where EDIT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +9.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 179 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 74 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 42 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
EDIT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.793) is normal, around the industry mean (3.037). P/E Ratio (-3.939) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which translates genome editing technology into a novel class of human therapeutics
Industry Biotechnology
Advertisement